Form 4 for BLFS BIOLIFE SOLUTIONS INC
Accepted 2026-02-26 00:00:00 ET · period of report 2026-02-24 · accession 0001628280-26-012472 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-26 | 2026-02-24 | BLFS | Aebersold Sarah | CHRO | A - Grant | — | +23.5K | 99.3K | +31% | — | |
| 2026-02-26 | 2026-02-24 | BLFS | Aebersold Sarah | CHRO | F - Tax | $22.65 | -5,734 | 93.6K | -6% | -$129.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-24 | A | A | 23,548 | — | 99,313 | D | — | — | (F1) The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to approximately 156% of the number of shares granted based on the registrant's total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| 2 | Common | Common Stock | 2026-02-24 | F | D | 5,734 | $22.65 | 93,579 | D | — | — | (F2) Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. |